Fidelity Investments
ALGS icon

Fidelity Investments’s Aligos Therapeutics ALGS Stock Holding History

Fidelity Investments’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,972
Closed -$46.3K – 5418
2025
Q4 		$46.3K Buy
+4,972
New +$46.9K ﹤0.01% 4154
2025
Q3 		– Sell
-10
Closed -$72 – 5371
2025
Q2 		$72 Buy
+10
New +$60 ﹤0.01% 5155
2023
Q4 		– Sell
-48
Closed -$896 – 5420
2023
Q3 		$896 Hold
48
– – ﹤0.01% 4656
2023
Q2 		$1.17K Buy
48
+8
+20% +$215 ﹤0.01% 4686
2023
Q1 		$874 Hold
40
– – ﹤0.01% 4755
2022
Q4 		$964 Sell
40
-1
-2% -$25 ﹤0.01% 4664
2022
Q3 		$1K Buy
41
+22
+116% +$731 ﹤0.01% 4623
2022
Q2 		$1K Sell
19
-199
-91% -$6.76K ﹤0.01% 4656
2022
Q1 		$12K Buy
+218
New +$17.5K ﹤0.01% 4181

Other funds holding ALGS

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SC
SummitTX Capital Fort Worth, Texas $3.2B AUM 41.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments's ALGS Position: Q1 2026 in Review

Fidelity Investments sold out of Aligos Therapeutics (ALGS) in Q1 2026, closing a stake of 4,972 shares — an estimated $46.3K sold.

Fidelity Investments first reported a position in ALGS in Q1 2022 and held it in 9 quarters. The position peaked at $46.3K in Q4 2025. 35 funds tracked by Wall St. Rank hold ALGS as of Q1 2026.

  • Fidelity Investments reported no remaining Aligos Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Fidelity Investments sold 4,972 Aligos Therapeutics shares in Q1 2026, an estimated $46.3K.
  • Fidelity Investments first reported a position in Aligos Therapeutics in Q1 2022 and held it in 9 quarters.
  • Fidelity Investments's Aligos Therapeutics position peaked at $46.3K in Q4 2025.
  • 35 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.